Conclusions
In conclusion, patients with larger LVMi at baseline experienced significantly greater cardiac reverse remodelling with empagliflozin than patients with a lower LVMi at baseline. Studies with larger cohorts and longer follow-ups are warranted to investigate the influence of baseline LVM on SGLT2i-mediated cardiac reverse remodelling and the treatment benefits received from treatment with empagliflozin.